When Christy Fennewald was 36, she felt a lump in one of her breasts, but a diagnostic ultrasound didn't pick up that it was suspicious. Nine months later, she was diagnosed with breast cancer and ...
AUSTIN, Texas, July 28, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new peer-reviewed paper published in Gastroenterology ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the Company’s first commercial coverage policies for its molecular residual ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has received written confirmation from the Centers for Medicare & ...
My husband’s cancer came back this summer after not being evident for almost two years. With advances in cancer surveillance, we now speak of cancer survivors being cancer-free far less frequently. If ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group ...
Natera, Inc. is a diagnostic company focusing on cfDNA tests in women's health, organ health, and oncology. Natera's MRD test, Signatera, demonstrated strong growth, with a 64% increase in processed ...
Zacks Investment Research on MSN
Natera files Signatera CDx PMA with FDA for bladder cancer MRD test
Natera NTRA recently announced the submission of a premarket approval (PMA) application to the FDA for its Signatera CDx test ...
AUSTIN, Texas, Jan. 22, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced new data recently presented on the clinical utility ...
Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...
Multi-cancer policy from BCBS of Louisiana covers CRC, Bladder, and IO monitoring AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results